Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Br J Nutr ; 97(3): 584-90, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-17313722

RESUMO

Many food components can influence satiety or energy intake. Combined together, these food components could represent an interesting dietary strategy in the prevention and treatment of obesity. The aims of this study were: 1) to determine the effect of a functional food in the form of a healthy meal course on subsequent energy intake and satiety; 2) to verify if it is possible to maintain palatability while preserving the satiating effects of the test meal. Thirteen subjects were invited to eat two lunch sessions: healthy and control meal courses (2090 kJ/meal). Anthropometric and ad libitum food intake measurements, and visual analogue scales (VAS) were performed during the two lunch sessions. The healthy main course acutely decreased energy intake during the rest of the meal (-744 kJ, P

Assuntos
Ingestão de Energia , Preferências Alimentares , Saciação , Paladar , Adulto , Antropometria , Apetite , Comportamento do Consumidor , Ingestão de Alimentos , Alimentos/economia , Comportamentos Relacionados com a Saúde , Humanos , Masculino
2.
Eur J Clin Pharmacol ; 63(2): 123-34, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17200837

RESUMO

OBJECTIVE: Topiramate (TPM) has been reported to reduce body weight beyond a placebo in the treatment of obese participants, but the effect of this agent on components of energy balance has not yet been established in humans. Thus, the aim of this study was to study the impact of TPM on food preferences, measures of satiety, food intake, resting metabolic rate (RMR), and 24-h energy expenditure. METHODS: The study design consisted of a 6-month, single-center, randomized, double-blind, parallel group, placebo-controlled trial with a 6-month open-label extension. The study included 68 sedentary men with abdominal obesity (waist circumference > or = 100 cm), of between 25 and 55 years of age, with a dyslipidemic profile and a body mass index (BMI) > or = 27 and < or = 40 kg/m(2). RESULTS: Treatment with TPM produced significant changes in anthropometric variables and body composition compared with placebo. However, at the end of the 1-year study, the placebo/TPM group showed similar weight loss and reduction in body fatness compared with the TPM/TPM group. For instance, at the end of the 12-month intervention, mean percentage of body weight loss from baseline was about -5% in both groups (-4 kg fat loss). Topiramate treatment reduced energy intake, be it in the context of an ad libitum buffet-type meal or under free living conditions. The 24-h daily energy expenditure (DEE) assessed by whole-body indirect calorimetry adjusted for body weight and age was not altered by TPM treatment. CONCLUSION: Topiramate treatment produced significantly greater weight loss than placebo and the majority of this loss was explained by a decrease in body fat stores. Most of the weight loss effect produced by TPM therapy was observed within a period of 6 months. Finally, TPM treatment had an impact on energy balance through a reduction in food intake that appears to have created an energy deficit of about 30,000-40,000 kcal compared with treatment with the placebo over 6 months.


Assuntos
Fármacos Antiobesidade/farmacologia , Metabolismo Energético/efeitos dos fármacos , Frutose/análogos & derivados , Obesidade/tratamento farmacológico , Redução de Peso/efeitos dos fármacos , Tecido Adiposo/efeitos dos fármacos , Adulto , Fármacos Antiobesidade/efeitos adversos , Fármacos Antiobesidade/uso terapêutico , Calorimetria Indireta , Método Duplo-Cego , Ingestão de Energia , Preferências Alimentares/efeitos dos fármacos , Frutose/efeitos adversos , Frutose/farmacologia , Frutose/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Resposta de Saciedade/efeitos dos fármacos , Topiramato
3.
Physiol Behav ; 89(1): 85-91, 2006 Aug 30.
Artigo em Inglês | MEDLINE | ID: mdl-16580033

RESUMO

Consumption of spiced foods or herbal drinks leads to greater thermogenesis and in some cases to greater satiety. In this regard, capsaicin, black pepper, ginger, mixed spices, green tea, black tea and caffeine are relevant examples. These functional ingredients have the potential to produce significant effects on metabolic targets such as satiety, thermogenesis, and fat oxidation. A significant clinical outcome sometimes may appear straightforwardly but also depends too strongly on full compliance of subjects. Nevertheless, thermogenic ingredients may be considered as functional agents that could help in preventing a positive energy balance and obesity.


Assuntos
Metabolismo Basal/efeitos dos fármacos , Cafeína/farmacologia , Estimulantes do Sistema Nervoso Central/farmacologia , Especiarias , Chá , Animais , Cafeína/efeitos adversos , Humanos , Especiarias/efeitos adversos , Especiarias/classificação , Termogênese/efeitos dos fármacos , Termogênese/fisiologia
4.
Br J Nutr ; 94(3): 432-6, 2005 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16176615

RESUMO

It has been reported that green tea has a thermogenic effect, due to its caffeine content and probably also to the catechin, epigallocatechin-3-gallate (EGCG). The main aim of the present study was to compare the effect of a mixture of green tea and Guarana extracts containing a fixed dose of caffeine and variable doses of EGCG on 24 h energy expenditure and fat oxidation. Fourteen subjects took part to this randomized, placebo-controlled, double-blind, cross-over study. Each subject was tested five times in a metabolic chamber to measure 24 h energy expenditure, substrate oxidation and blood pressure. During each stay, the subjects ingested a capsule of placebo or capsules containing 200 mg caffeine and a variable dose of EGCG (90, 200, 300 or 400 mg) three times daily, 30 min before standardized meals. Twenty-four hour energy expenditure increased significantly by about 750 kJ with all EGCG-caffeine mixtures compared with placebo. No effect of the EGCG-caffeine mixture was observed for lipid oxidation. Systolic and diastolic blood pressure increased by about 7 and 5 mmHg, respectively, with the EGCG-caffeine mixtures compared with placebo. This increase was significant only for 24 h diastolic blood pressure. The main finding of the study was the increase in 24 h energy expenditure with the EGCG-caffeine mixtures. However, this increase was similar with all doses of EGCG in the mixtures.


Assuntos
Cafeína/administração & dosagem , Catequina/análogos & derivados , Estimulantes do Sistema Nervoso Central/administração & dosagem , Metabolismo Energético/efeitos dos fármacos , Paullinia , Chá , Adulto , Análise de Variância , Área Sob a Curva , Bebidas , Calorimetria Indireta , Catequina/administração & dosagem , Estudos Cross-Over , Relação Dose-Resposta a Droga , Método Duplo-Cego , Humanos , Masculino , Pessoa de Meia-Idade , Oxirredução , Extratos Vegetais , Termogênese
5.
Curr Vasc Pharmacol ; 3(2): 185-93, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15853638

RESUMO

The increase in obesity prevalence is problematic as this condition is associated with health complications such as diabetes and cardiovascular diseases, more particularly when the excess body fat is stored in the deep abdominal region. The mainstay of therapy consists of behavior modification related to obesity such as overeating and physical inactivity. When these lifestyle modifying attempts fail, the use of anti-obesity drugs is warranted. Drug treatment is often indicated but is somewhat limited by the minimal number of well tolerated drugs that have proven to have long-term efficacy in maintaining body weight loss. The currently available drugs, sibutramine and orlistat, appear modestly effective in promoting weight loss. Ongoing studies continue to evaluate other drug treatments that may result in body weight reduction through a number of different mechanisms. Thus, the aim of this review is to present an overview of the current drugs available (particularly sibutramine and orlistat) as well as potential future candidates, and the impact of these agents on obesity and cardiovascular physiology. Furthermore, the therapeutic paradox of sibutramine in preventing obesity will be discussed as well as the beneficial impact of physical exercise on cardiac economy.


Assuntos
Fármacos Antiobesidade/uso terapêutico , Fenômenos Fisiológicos Cardiovasculares/efeitos dos fármacos , Obesidade/tratamento farmacológico , Obesidade/fisiopatologia , Animais , Depressores do Apetite/uso terapêutico , Doenças Cardiovasculares/etiologia , Ensaios Clínicos como Assunto , Ciclobutanos/uso terapêutico , Humanos , Lactonas/uso terapêutico , Obesidade/complicações , Obesidade/epidemiologia , Orlistate , Piperidinas/uso terapêutico , Pirazóis/uso terapêutico , Rimonabanto , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...